Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirnaomics has licensed a polypeptide nanoparticle technology. The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of Histidine-Lysine polymer (HKP) for siRNA therapeutics, in the areas of wound healing and ocular diseases.
Subscribe to our email newsletter
Sirnaomics is developing nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles, ligand-directed nanoparticles, and infrared-activated nanoparticles, for various types of therapeutic applications.
Patrick Lu, president and CEO of Sirnaomics, said: “Licensing the Histidine-Lysine polymer nanoparticle technology is rooted in our long time experience and in-depth understanding of this unique class of polypeptides as an siRNA delivery vehicle. The two year collaboration between Mixson and Sirnaomics, supported by a Maryland Industrial Partnerships (MIPS) grant, facilitated progress of our scarless wound healing program and resulted in the discovery and development of STP705 (Cutasil).
“The collaboration and licensing agreement have provided an important foundation for Sirnaomics’ technology and product development. We are currently engaging in several similar collaborative efforts and we believe that this is a great way to create value and ensure the credibility of a novel technology.”
David Evans, vice president of discovery research at Sirnaomics, said: “STP705 is a topically applied formulation for delivery of the siRNAs to the wound site and it has demonstrated accelerated wound repair yet with reduced scar formation in both murine and swine excisional wound models.”